Ocular Therapeutix Company Profile (NASDAQ:OCUL)

Analyst Ratings

Consensus Ratings for Ocular Therapeutix (NASDAQ:OCUL) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $32.00 (589.66% upside)

Analysts' Ratings History for Ocular Therapeutix (NASDAQ:OCUL)
Show:
DateFirmActionRatingPrice TargetActions
7/26/2016BTIG ResearchReiterated RatingBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Morgan StanleyReiterated RatingOverweight$17.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/10/2016Royal Bank Of CanadaReiterated RatingOutperform$48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/5/2015Nomura Holdings Inc.Initiated CoverageBuy$46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2015Oppenheimer Holdings Inc.Boost Price TargetOutperform$42.00 -> $49.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Ocular Therapeutix (NASDAQ:OCUL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q116($0.43)($0.44)$458.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q415($0.47)($0.43)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.38)($0.47)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.33)($0.45)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2015Q115($0.39)($0.35)$0.30 million$0.43 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2015Q4($0.38)($0.37)$0.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q3 14($0.55)($0.48)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ocular Therapeutix (NASDAQ:OCUL)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Ocular Therapeutix (NASDAQ:OCUL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ocular Therapeutix (NASDAQ:OCUL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/9/2016Amarpreet SawhneyCEOBuy10,000$6.70$67,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2015Amarpreet SawhneyCEOBuy10,000$8.25$82,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015James FortuneCOOSell9,470$17.16$162,505.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2015Amarpreet SawhneyCEOBuy15,000$16.50$247,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Charles M WardenDirectorSell320,000$22.00$7,040,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2015Charles M WardenDirectorSell427,000$22.00$9,394,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2015Svlsf Iv, LlcMajor ShareholderSell1,119,000$22.00$24,618,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2014Amarpreet SawhneyCEOBuy76,922$13.00$999,986.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2014Svlsf Iv, LlcMajor ShareholderBuy715,380$13.00$9,299,940.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ocular Therapeutix (NASDAQ:OCUL)
DateHeadline
07/25/16 05:44 PMUPDATE 1-FDA rejects Ocular's post-operative eye pain treatment
07/25/16 05:44 PMOcular Therapeutix : trade; Receives Complete Response Letter from FDA for its NDA for DEXTENZA™ for the Treatment of Post-Surgical Ocular Pain
07/25/16 05:44 PMOcular Shares Fall After FDA Rejects Eye Pain Drug
07/25/16 05:44 PMFDA rejects Ocular Therapeutix' Dextenza post-operative pain indication
07/25/16 05:44 PMOcular Therapeutix Inc (OCUL) Options Volume Pops on FDA Diss
07/25/16 01:37 PM[$$] Ocular Shares Fall After FDA Rejects Eye Pain Drug -
07/25/16 11:21 AMSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Ocular Therapeutix, Inc. (OCUL) - [PR Newswire] - NEW YORK, July 25, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Ocular Therapeutix, Inc. ...
07/25/16 10:43 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ocular Therapeutix, Inc. - OCUL - [PR Newswire] - NEW YORK, July 25, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ocular Therapeutix, Inc. ("Ocular" or the "Company") (NASDAQ: OCUL). Such investors ...
07/25/16 10:02 AMPre-Market Stocks Briefing: Ocular Therapeutix Inc (NASDAQ:OCUL), CombiMatrix Corp (NASDAQ:CBMX) - Review Fortune
07/25/16 08:57 AMOcular Therapeutix Gets Complete Response Letter From FDA For Its NDA For DEXTENZA -
07/25/16 08:38 AMOcular stock drops 7% after eye pain drug fails to get FDA approval -
07/25/16 08:19 AMFDA rejects Ocular's post-operative eye pain treatment - [Reuters] - Drug developer Ocular Therapeutix Inc said the U.S. Food and Drug Administration had denied approval for its treatment for post-operative eye pain. The company said the FDA raised concerns related to its manufacturing process after an inspection of its facility. The health regulator, in a letter, did not provide any details of the manufacturing deficiencies, Ocular said on Monday.
07/25/16 07:33 AMFDA rejects Ocular Therapeutix post-operative eye pain treatment - [Reuters] - Drug developer Ocular Therapeutix Inc said the U.S. Food and Drug Administration had denied approval for its treatment for post-operative eye pain. The company said on Monday that the FDA raised concerns ...
07/25/16 07:08 AMOCULAR THERAPEUTIX, INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
07/25/16 07:08 AMOcular Therapeutix™ Receives Complete Response Letter from FDA for its NDA for DEXTENZA™ for the Treatment of Post-Surgical Ocular Pain - [at noodls] - No efficacy or safety issues raised by FDA Outstanding items pertain to manufacturing process and controls BEDFORD, Mass.--(BUSINESS WIRE)--Jul. 25, 2016-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical ...
07/25/16 07:06 AM8:06 am Ocular Therapeutix receives CRL from the FDA regarding its NDA for DEXTENZA 0.4 mg, for intracanalicular use in the treatment of ocular pain occurring after ophthalmic surgery -
07/22/16 05:28 PMWhat's in Ocular Therapeutix Inc After Today's Huge Increase? - Press Telegraph
07/22/16 05:28 PMIncreased Volatility Noted on Shares of: Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Engelwood Daily
07/20/16 06:22 PMShares Jumping Higher in Session: Ocular Therapeutix, Inc. (NASDAQ:OCUL) - TGP
07/20/16 06:22 PMWhat's Ahead for Ocular Therapeutix Inc After Forming Multiple Bottom Pattern? - Press Telegraph
07/20/16 08:32 AMStock Moving Lower for the Month; Investor Update on Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Engelwood Daily
07/20/16 08:32 AMOcular Therapeutix Inc Stock Technicals Hit Extreme Weakness - CML News
07/17/16 04:58 PMShares Moving Down on the Week: Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Engelwood Daily
07/17/16 04:58 PMNext Weeks Broker Price Targets For Ocular Therapeutix, Inc. (OCUL) - Fiscal Standard
07/16/16 08:53 AMShares Experiencing a Downtrend: Ocular Therapeutix, Inc. (NASDAQ:OCUL) - TGP
07/16/16 08:53 AMHow Many Ocular Therapeutix Inc (NASDAQ:OCUL)'s Analysts Are Bullish? - Consumer Eagle
07/15/16 10:33 AMShare Volatility Watch for: Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Engelwood Daily
07/15/16 10:33 AMEye on Stock Volatility for: Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Engelwood Daily
07/15/16 10:33 AMIs Selling Ocular Therapeutix Inc Here a Winning Strategy? - Consumer Eagle
07/13/16 08:32 AMSession Volatility Review for: Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Engelwood Daily
07/12/16 09:56 AMBiotech Top Gainers: Esperion Therapeutics, Inc. (NASDAQ:ESPR), Ocular Therapeutix, Inc. (NASDAQ:OCUL ... - KC Register
07/11/16 05:37 PMOcular Therapeutix, Inc. (NASDAQ:OCUL) surged 11.24%: Fenix Parts, Inc. (NASDAQ:FENX), Jacksonville Bancorp Inc ... - KC Register
07/11/16 05:37 PMBRIEF-Prudential Financial reports 12 pct passive stake in Ocular Therapeutix - Reuters
07/09/16 05:01 PMBroker Outlook For Ocular Therapeutix, Inc. (OCUL) - Fiscal Standard
07/06/16 10:13 AMOcular Therapeutix™ to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference - Stockhouse
07/06/16 07:11 AMOcular Therapeutix™ to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference - [at noodls] - BEDFORD, Mass.--(BUSINESS WIRE)--Jul. 6, 2016-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases ...
07/05/16 10:06 AMShare Performance Recap for: Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Press Telegraph
07/05/16 10:06 AMBroker Outlook For The Week Ahead Ocular Therapeutix, Inc. (OCUL) - Fiscal Standard
07/03/16 04:58 PMCompany Stock Lower on the Week Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Engelwood Daily
07/02/16 08:22 AMInvestor News: Ocular Therapeutix Inc (NASDAQ:OCUL) faces Investigation
07/01/16 05:36 PMDoes Ocular Therapeutix Inc Have Any Gas After Today's Huge Decline? - Press Telegraph
07/01/16 05:36 PMInvestor News: Ocular Therapeutix Inc (NASDAQ:OCUL) faces Investigation - GroundReport
07/01/16 05:36 PMRecently Issued Stock Ratings For Ocular Therapeutix, Inc. (OCUL) - Fiscal Standard
06/29/16 08:25 AMCould Ocular Therapeutix Inc Lose Strenght? The Stock Increases A Lot Today - Press Telegraph
06/28/16 05:32 PMTrending Tickers: Ocular Therapeutix, Inc. (NASDAQ:OCUL), Weight Watchers International, Inc. (NYSE:WTW ... - KC Register
06/28/16 05:32 PMStock Volatility in Review: Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Engelwood Daily
06/23/16 03:36 PMOCULAR THERAPEUTIX, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financia -
06/20/16 05:27 PMQCR Holdings Inc. (NASDAQ:QCRH) Went Down -3.63%: Ocular Therapeutix, Inc. (NASDAQ:OCUL), Equifax Inc ... - KC Register
06/18/16 09:49 AMOcular Therapeutix Inc. (OCUL) is Trading Lower on Unusual Volume for June 16 - Equities.com
06/16/16 09:48 AMOcular Therapeutix Inc. (OCUL) is Trading Lower on Unusual Volume for June 14 - Equities.com

Social

About Ocular Therapeutix

Ocular Therapeutix logoOcular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company's bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company's product pipeline includes marketed candidate ReSure Sealant and products under development, such as OTX-DP, OTX-TP, OTX-MP and anti-VEGF hydrogel depot. The Company's lead product candidates are OTX-DP and OTX-TP. The OTX-DP product candidate incorporates the corticosteroid dexamethasone as an active pharmaceutical ingredient in its punctum plug. The OTX-TP product candidate incorporates the prostaglandin analog travoprost as an active pharmaceutical ingredient in its punctum plug.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OCUL
  • CUSIP:
Key Metrics:
  • Previous Close: $4.64
  • 50 Day Moving Average: $5.40
  • 200 Day Moving Average: $8.33
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $114.91M
  • Beta: 1.23
  • Current Year EPS Consensus Estimate: $-1.78 EPS
  • Next Year EPS Consensus Estimate: $-2.36 EPS
Additional Links:
Ocular Therapeutix (NASDAQ:OCUL) Chart for Wednesday, July, 27, 2016